Literature DB >> 19793280

A pilot study of the SNOT 22 score in adults with no sinonasal disease.

S Gillett1, C Hopkins, R Slack, J P Browne.   

Abstract

OBJECTIVE: To determine the SNOT 22 score in a normal population. STUDY
DESIGN: Analysis of SNOT 22 scores participants with no sinonasal disease.
SETTING: Bath, UK. PARTICIPANTS: 116 participants from a local hospital and tennis club.
RESULTS: Results were obtained from 54 men and 62 women with a mean age of 40 (range 19-75). SNOT score ranged from 0-50 with a mean score of 9.3 (95% confidence interval range of 7.5-11.1). The modal score was 0 and the median score 7 (95% confidence interval range of 5-8).
CONCLUSION: Due to the scewed nature of the data, the median score (7) is taken as the normal SNOT 22 score. We recommend that in an clincial situation a SNOT 22 score of 7 be used a a guide for "normal", and that care should be taken when suggesting treatment on patients with a score below this level.

Entities:  

Mesh:

Year:  2009        PMID: 19793280     DOI: 10.1111/j.1749-4486.2009.01975.x

Source DB:  PubMed          Journal:  Clin Otolaryngol        ISSN: 1749-4478            Impact factor:   2.597


  20 in total

1.  Does septoplasty enhance the quality of life in patients?

Authors:  Maija L Hytönen; Markus Lilja; Antti A Mäkitie; Harri Sintonen; Risto P Roine
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-01-25       Impact factor: 2.503

2.  Efficacy of nasal mometasone for the treatment of chronic sinonasal disease in patients with inadequately controlled asthma.

Authors:  Anne E Dixon; Mario Castro; Rubin I Cohen; Lynn B Gerald; Janet T Holbrook; Charles G Irvin; Shyam Mohapatra; Stephen P Peters; Sobharani Rayapudi; Elizabeth A Sugar; Robert A Wise
Journal:  J Allergy Clin Immunol       Date:  2014-08-28       Impact factor: 10.793

3.  Impact of postoperative endoscopy upon clinical outcomes after endoscopic sinus surgery.

Authors:  Rodney J Schlosser; Kristina Storck; Timothy L Smith; Jess C Mace; Luke Rudmik; Arash Shahangian; Zachary M Soler
Journal:  Int Forum Allergy Rhinol       Date:  2015-10-13       Impact factor: 3.858

4.  Low 22-item sinonasal outcome test scores in chronic rhinosinusitis: Why do patients seek treatment?

Authors:  Joshua M Levy; Jess C Mace; Luke Rudmik; Zachary M Soler; Timothy L Smith
Journal:  Laryngoscope       Date:  2016-07-05       Impact factor: 3.325

5.  Review article: outcomes in endoscopic sinus surgery.

Authors:  Edward Noon; Claire Hopkins
Journal:  BMC Ear Nose Throat Disord       Date:  2016-08-05

6.  Acoustic rhinometry and video endoscopic scoring to evaluate postoperative outcomes in endonasal spreader graft surgery with septoplasty and turbinoplasty for nasal valve collapse.

Authors:  Bree Erickson; Robert Hurowitz; Caroline Jeffery; Khalid Ansari; Hamdy El Hakim; Erin D Wright; Hadi Seikaly; Sam R Greig; David W J Côté
Journal:  J Otolaryngol Head Neck Surg       Date:  2016-01-12

7.  Intra-oral low level laser therapy in chronic maxillary sinusitis: A new and effective recommended technique.

Authors:  Hamed Mortazavi; Hamidreza Khalighi; Ali Goljanian; Robab Noormohammadi; Saeed Mojahedi; Siamak Sabour
Journal:  J Clin Exp Dent       Date:  2015-12-01

8.  Metastatic renal cell carcinoma to the sinonasal cavity: a case series.

Authors:  Aaron K Remenschneider; Peter M Sadow; Derrick T Lin; Stacey T Gray
Journal:  J Neurol Surg Rep       Date:  2013-05-09

9.  The reliability and validity of the persian version of sinonasal outcome test 22 (snot 22) questionnaires.

Authors:  Maryam Jalessi; Mohammad Farhadi; Seyyed Kamran Kamrava; Ebrahim Amintehran; Alimohammad Asghari; Mohsen Rezaei Hemami; Alireza Mobasseri; Mohammadreza Masroorchehr
Journal:  Iran Red Crescent Med J       Date:  2013-05-05       Impact factor: 0.611

10.  Long-term quality of life after endoscopic removal of sinonasal inverted papillomas: a 6-year cohort analysis in a tertiary academic hospital.

Authors:  Anusha van Samkar; Christos Georgalas
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-08-18       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.